Sage Therapeutic (SAGE) - Stock Price & Dividends

Sage Therapeutics, a biopharmaceutical company traded on the NASDAQ under the symbol SAGE, focuses on developing and selling medications aimed at improving brain health. They have a diverse range of product candidates with innovative approaches to addressing various mental health conditions.

Among their key products, ZULRESSO is a controlled substance injection designed to treat postpartum depression in adults. Zuranolone, another promising compound, has advanced to Phase III trials for postpartum and major depressive disorders, while also being investigated for use in treatment-resistant depression, anxiety disorders, and bipolar depression.

Further expanding their portfolio, Sage Therapeutics is exploring SAGE-324, a compound currently in Phase II trials targeting essential tremors. They have also introduced SAGE-689, focusing on acute GABA hypofunction, and SAGE-718, an NMDA receptor modulator being tested for various conditions such as depression, Huntington's disease, and Alzheimer's.

Collaborations play a vital role in their development strategy. Notably, they have partnered with Shionogi & Co., Ltd. to enhance the presence of zuranolone in Japan, Taiwan, and South Korea. Additionally, a collaboration and license agreement with Biogen MA Inc. enables joint efforts in developing and marketing SAGE-217 and SAGE-324 products.

Established in 2010 and based in Cambridge, Massachusetts, Sage Therapeutics was originally known as Sterogen Biopharma, Inc. before rebranding in September 2011. For more information on their innovative treatments, visit their website at https://www.sagerx.com.